Focused on life sciences · Providing high-quality reagents and laboratory solutions Service Hotline 021-55086080 Business Email shfz_biot@163.com
FZ
INSIGHT / DETAIL

NK Cell Therapy: From Backup to Clinical Application

Company News · 2023-12-07

◷2023-12-07 ◉admin ◎Source:本站 ▤Company News
NK Cell Therapy: From Backup to Clinical Application

NK cells bridge innate and adaptive immunity and are among the first cell populations shown to have strong tumour-killing activity. They include CD56brightCD16dim cells, which mainly secrete cytokines, and CD56dimCD16bright cells, which mainly mediate cytotoxicity.

Clinical NK cell therapy has developed rapidly in recent years. NK cells are non-specific killer cells with broad, efficient activity and no target-off-tumour risk. They can attack cancer and virus-infected cells without prior sensitization.

Two key mechanisms

In the “missing-self” model, healthy cells display MHC class I molecules, which are recognized by inhibitory KIR receptors on NK cells. Tumour cells often lose or downregulate MHC class I to escape immune surveillance. When NK cells encounter these cells, the missing MHC class I signal reduces inhibition and allows NK cells to kill the abnormal cells.

In the “stress-induced” model, activating receptors such as NKG2D recognize stress ligands including MICA/B and ULBP3. Conditions such as malignant transformation, viral infection or physicochemical stress increase these ligands, making abnormal cells more visible to NK cells and triggering cytotoxic activity.

With further basic and clinical research, NK cells are expected to realize their potential as a powerful cancer immunotherapy.

← Back to listShanghai Fuzhi Biotechnology Co., Ltd.